HK's Biostime to buy Australian vitamin maker Swisse for over US$1b: media
Add BT as a preferred source[SYDNEY] Hong Kong-listed dietary supplements company Biostime International Holdings has agreed to buy Australian vitamin maker Swisse Wellness for more than A$1.5 billion (S$1.5 billion), Australian media reported on Thursday.
The company beat Shanghai Pharmaceuticals Holding and Chinese private equity firm Hony Capital in a sale managed by Goldman Sachs Group Inc, the Australian newspaper and Fairfax Media said in reports, citing unnamed sources.
Swisse and Goldman Sachs were not immediately available for comment. Biostime issued a statement saying it had requested a trading halt for its shares, without giving an explanation.
REUTERS
Share with us your feedback on BT's products and services
TRENDING NOW
Buyer for England striker Harry Kane’s former mansion must pay £3.4 million after abandoning deal
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
EU and Asean at 50: time for bold action
